Danaher said its operating profit margin decreased 10 basis points to 19.0% over the 3-month period and increased 180 basis points to 19.8% on a cumulative basis over the 9-month period, from 19.1% and 18.0%, respectively.

1. 01

   Danaher said its operating profit margin decreased 10 basis points to 19.0% over the 3-month period and increased 180 basis points to 19.8% on a cumulative basis over the 9-month period, from 19.1% and 18.0%, respectively.

2. 02

   The company said the fair value adjustment to inventory related to the Masimo Acquisition was reflected in cost of sales for 3 months in $84 million and for 9 months in $130 million. The company said it unfavorably affected the operating profit margin comparison for Q3 by 130 basis points.

3. 03

   Diagnostics segment total sales increased 17.0% over the 3-month period and 7.5% over the 9-month period, primarily as a result of the Masimo Acquisition, the company said. Core sales excluding respiratory testing rose 7.0% and 5.0%, respectively.

4. 04

   Danaher said operating cash flow for the first 9 months of 2026 was approximately $4.7 billion, an increase of $443 million (10%) from the same period a year earlier. It said cash and cash equivalents were approximately $5.7 billion as of September 25, 2026.

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Structured SEC financial data for this filing is not available yet. Please check the figures in the SEC filing.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.